SAN DIEGO, Sept. 20 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that Patrick Sullivan, former chairman, president and chief executive officer of Cytyc Corporation, has been elected to its board of directors. Gen-Probe's board now has 10 members, including eight independent directors.
"We are delighted that Pat has agreed to join Gen-Probe's already strong board," said Hank Nordhoff, the Company's chairman. "We expect to benefit greatly from his experiences leading a multi-billion-dollar growth company, and from his deep knowledge of diagnostics and women's health."
Mr. Sullivan, 58, joined Cytyc in 1991 as vice president, sales and marketing. He became president, CEO and a director in 1994, and added the chairman's title in 2002. He remained in those roles until the company's merger with Hologic in 2007. Mr. Sullivan now leads Constitution Medical Investors, a Boston-based private investment firm in partnership with Warburg Pincus, and is also a director of PerkinElmer. He graduated with distinction from the U.S. Naval Academy and earned an M.B.A., also with distinction, from Harvard University.
About Gen-ProbeGen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility. Gen-Probe has approximately 27 years of expertise in nucleic acid testing (NAT), and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,300 people. For more information, go to www.gen-probe.com.
Caution Regarding Forward-Looking StatementsAny statements in this press release about our expectations, beliefs, plans, objectives, assumptions, future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that Gen-Probe may not be able to retain its key employees and directors. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of subsequent events.Contact:Michael Watts
Vice president, investor relations and corporate communications
|SOURCE Gen-Probe Incorporated|
Copyright©2010 PR Newswire.
All rights reserved